Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women

The primary hypothesis is: "Comparing to control group (Calcium+VitD), Bazedoxifene group (20mg daily+ calcium+VitD) is efficient in reducing BMD in spine at 12 months of treatment. in postmenopausal women switching from daily, weekly or monthly bisphosphonates therapy. It is a non-inferiority study of Bazedoxifene compared to biphosphonates, being each patient its own control from the baseline. It is a superiority study of Bazedoxifene compared to Calcium+VitD.

Taking into account the difference in the percentage change observed in the total BMD of the spine during 12 months in those patients treated with Bazedoxifene+Ca+VitD at least 110 patients should be included, 55 in each arm of treatment.

This simple size is going to allow us to detect the differences in the percentage change observed in the total BMD of the spine during 12 months between the two treatment arms, being the same or over 0.25%, with a significance level of 95%, an 80% power. It is estimated a standard deviation of 0.5%, and a 10% lost follow-up rate.

Inclusion criteria

• Ambulatory postmenopausal women 55 years or older at screening
• Have received daily, weekly or monthly oral bisphosphonates at least for 3 years and treatment change is indicated (not responses to bisphosphonates, for bad tolerability or for the potential risk of side effects in a long term treatment with bisphosphonates-indicated by Federal Drug Administration, European Medicines Agency.
• Subjects has stop bisphosphonates therapy no more than one month before screening visit for subjects in daily or weekly bisphosphonates
• Subjects has stop bisphosphonates therapy no more than two months before screening visit for subjects in monthly bisphosphonates
• Screening T-score at the lumbar spine ≤ -2.0 to -4.0 by Dual X ray Absorptiometry (DXA) scan
• At least 2 lumbar vertebrae must be evaluable by DXA
• Al least one hip must be evaluable by DXA (for secondary objectives)

Exclusion criteria

• Any disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
• Current use of medication prescribed for osteoporosis other than oral bisphosphonates
• Subjects who had received intravenous bisphosphonates or fluoride (except for dental treatment)
• Subjects who had received any Selective Estrogens Receptor Modulator (SERM), anabolic steroids, systemic hormone replacement, calcitonin or calcitriol within 3 months.
• Subjects who had received strontium ranelate, parathyroid hormone (PTH) or PTH derivates within 1 year.
• Hyper or hypothyroidism, current hyper or hypoparathyroidism
• History of Venous Thromboembolism Event (VTE)
• Significantly impaired renal function as determined by estimated Glomerular Filtration Rate less 35 mL/min
• Hyper or hypocalcemia
• Vitamin D deficiency (serum 25 (OH) vit D level < 20 ng/mL (< 50nmol/L)
• Any condition that could result in impaired calcium metabolism or metabolic bone disease that could interfere with interpretation findings